Swedish clinical-stage pharmaceutical company Vicore Pharma Holding AB (STO:VICO) announced on Wednesday that the US Food and Drug Administration (FDA) has granted Fast Track designation to its lead candidate, buloxibutid, for the treatment of idiopathic pulmonary fibrosis (IPF).
Buloxibutid, a first-in-class AT2 receptor agonist, has the potential to modify the disease progression of IPF by promoting alveolar repair and resolving fibrosis.
Fast Track designation aims to expedite the development of drugs for serious or life-threatening conditions. Vicore plans to leverage this designation to expedite the development and potential approval of buloxibutid.
The Phase 2b ASPIRE trial evaluating the safety and efficacy of buloxibutid in IPF patients is currently enrolling.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval